Goodwin Biotechnology’s CSO Muctarr Sesay, Ph.D., discusses the concept behind opioid conjugate vaccines for the treatment of opioid use disorder and how the CDMO is applying its decades of bioconjugation manufacturing experience to advance vaccine candidates to the clinic.
.svg)
